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Abstract
Background: The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of
chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received
conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir
with or without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both regimens in Germany.
Methods: We set up a Markov model with a lifetime horizon to simulate immediate treatment success and
long-term disease progression for treatment-naive patients. The model analyzes both short-term and long-term
costs and benefits from the perspective of the German Statutory Health Insurance. We apply the efficiency frontier
method, which was suggested by German Institute for Quality and Efficiency in Health Care for cost-effectiveness
analysis in Germany.
Results: The efficiency frontier is defined by dual therapy and first generation direct-acting antiviral Boceprevir,
yielding a maximum of € 1,447.69 per additional percentage point of sustained virologic response gained. Even
without rebates, Sofosbuvir/Simeprevir is very close with € 1,560.13 per additional percentage point. It is both more
effective and less expensive than Sofosbuvir/Ribavirin.
Conclusions: In addition to higher sustained virologic response rates, new direct-acting antivirals save long-term
costs by preventing complications such as liver cirrhosis, hepatocellular carcinoma and ultimately liver transplants,
thereby offsetting part of higher drug costs. Our findings are in line with the guidance published by German
Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends Sofosbuvir/Simeprevir for
Interferon ineligible or intolerant patients.
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Background
Hepatitis C is one of the most common chronic infectious
diseases worldwide and in Germany. The total number of
patients infected with hepatitis C virus (HCV) is declining
in Germany, with an estimated 4,980 new infections in
2013 [1]. In contrast to the declining number of patients,
severe long-term complications such as decompensated
cirrhosis (DCC), hepatocellular carcinoma (HCC) and ul-
timately liver transplants (LT) are estimated to be increas-
ing due to the ageing of the existing infected population.
Of the HCV-infected patients in Germany, 62 % are
infected with HCV genotype 1, which is most difficult to
treat [2].
Recently approved direct-acting antiviral agents
(DAA) have improved sustained virologic response (SVR)
rates compared to the classic combination therapy of
PegInterferon (IFN) and Ribavirin (RBV; combination
with IFN: PR). Despite higher SVR rates close to 100 %,
high treatment costs have stirred a public debate on the
pricing of recently approved DAAs [3, 4].
While triple therapy with first generation protease
inhibitors (PI) Boceprevir or Telaprevir improved SVR
rates compared to PR, IFN was still required with both
agents. One of the greatest advantages of new DAAs is
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the advent of IFN-free treatment regimens. IFN-free
therapies provide dramatically increased SVR rates com-
pared to first-generation DAAs and avoid IFN’s side
effects like depression, anxiety and fatigue, which in
many cases has negative effects on patients’ ability to
work [5]. Another advantage of recently approved DAAs
are shorter treatment durations, which can contribute to
a better compliance.
As of August 2014, two treatment regimens are recom-
mended for IFN-free therapy of HCV genotype 1 infection
by German Society for Gastroenterology, Digestive and
Metabolic Diseases (DGVS) guidelines [6]:
 Sofosbuvir (SOF) and Simeprevir (SMV)
combination therapy with or without RBV for
12 weeks
 SOF and RBV combination therapy for 24 weeks
Since the approval of DAAs, HCV therapy has
played a major economic role in the German Statutory
Health Insurance (SHI) funds. In 2013, the German SHI
funds spent € 48.6 mn on Telaprevir and € 19.0 mn on
Boceprevir [7].
In 2011, Germany introduced early benefit assess-
ments and rebate negotiations as a measure of regulating
pharmaceutical reimbursement [8]. After approval for
the German market, pharmaceutical manufacturers are
free to set a price for one year. Within that one year
after approval, all prices of newly approved drugs need
to be negotiated with the German SHI funds. The out-
come of the negotiations is a rebate agreement, which
comes into effect one year after approval in Germany [9].
Negotiations for the rebate agreement are based on a
6-month early benefit assessment, which determines
additional benefits of the new therapy compared to an
existing alternative therapy [10]. Early benefit assessments
are conducted by German Federal Joint Committee
(GBA). GBA’s assessment in turn relies on a 3-month as-
sessment by German Institute for Quality and Efficiency
in Health Care (IQWIG).
The outcomes of cost-effectiveness analyses with the effi-
ciency frontier approach are maximum reimbursable prices.
Under current German legislation, no cost-effectiveness
analysis is involved in the process of the initial rebate
negotiations [11]. However, cost-effectiveness analysis can
be requested by either negotiating party as a base for fur-
ther negotiations, once a first rebate agreement has been
reached, i.e., the maximum reimbursable price would
serve as a base for a new rebate negotiation between
manufacturer and SHI funds. We aim to analyze the cost-
effectiveness of DAAs for IFN-free therapies in this
context.
Cost-effectiveness analyses are conducted by IQWIG
and they are based on the efficiency frontier method
[12, 13]. IQWIG’s method has previously been criticized
because it does not use quality-adjusted life years (QALYs)
as a measure of patient benefits. Contrary to approaches
based on QALYs, German IQWIG requires the definition
of specific clinical parameters as a measure of patient
benefits, i.e., the method is not suitable to define a global
threshold per QALY gained, as practiced in England and
Wales [14].
Application of IQWIG’s efficiency frontier method re-
quires the assessment of previously existing therapies.
The ratio of previous increases in effectiveness and costs
determines the efficiency frontier. This was heavily criti-
cized by health economists [14, 15]. The results of effi-
ciency frontier analyses depend on the benefits and costs
of previously existing therapies, even though these ther-
apies have never been subject to health technology as-
sessment and no willingness-to-pay can be derived from
the prices, which could previously be unilaterally deter-
mined by manufacturers.
If the ratio of previous gains in benefits and costs has
been relatively expensive (i.e., relatively higher costs per
clinical benefit unit), the efficiency frontier approach
leads to higher maximum reimbursable prices for new
approvals, too. This might not be desired from a regula-
tory perspective. Another problem of application can
arise if multiple efficiency frontiers need to be computed
to reflect the relevance of more than one clinical param-
eter. Naturally, the results of different efficiency frontiers
may vary, potentially leading to conflicting results. IQWIG
suggested to aggregate specific efficiency frontier results
based on patient preferences as found by analytic hier-
archy processes or conjoint analyses [16–18]. We aim to
analyze whether the problems outlined above prevent
useful results if the efficiency frontier method is applied to
DAAs for HCV in Germany.
Methods
Both IQWIG and GBA have accepted SVR rates as the
most important clinical parameter determining the suc-
cess of antiviral therapy for patients suffering from
chronic HCV infection. In its early benefit assessments
of SOF and SMV, German Federal Joint Committee de-
fined both classic dual therapy (PR) and triple therapy
with first generation PIs (Boceprevir or Telaprevir) as
appropriate comparators. Therefore, we define the effi-
ciency frontier with PR and Boceprevir triple therapy as
Boceprevir was the first PI to be approved in Germany.
We model the cost-effectiveness of the two compara-
tors and the two IFN-free therapies with an extended
Markov model, which is also used for analysis in the
United Kingdom and in Japan [19, 20]. The model simu-
lates the pathways of treatment-naive patients in all pos-
sible states of fibrosis (F0-F4). The model has a lifetime
time horizon with a cycle length of one year. The cycle
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length is consistent with previous economic models and
reflects the relatively slow progression rate for chronic
HCV infection [21, 22].
All modeling characteristics were adapted to reflect
clinical practice in Germany. Effectiveness analysis is
based on GBA’s assessment of PR and Boceprevir triple
therapy as part of early benefit assessments. However,
no IFN-free therapy has been assessed by GBA yet.
Therefore, benefit analysis of IFN-free regimens is only
based on the recommendations published by DGVS [6].
Therefore, the model was extended to incorporate suit-
able studies to simulate treatment with IFN-free regi-
mens. For SOF/SMV, the COSMOS trial was included in
the model, as it reports SVR rates for treatment naive pa-
tients after 12 weeks [23]. For SOF/RBV the QUANTUM
trial results were used [24].
We conducted a Pubmed search for 'hepatitis c cost
germany' to adapt the model to German prices. Out of
65 hits, only 2 studies could be identified as reporting
original German cost data for HCV [25, 26]. All costs
used in the model are in 2014 Euros and were dis-
counted by 3 %, as suggested by IQWIG. All drug costs
reflect German prices as of August 2014 (according to
Lauer-Taxe).
The model analyzes two components of health economic
interest: The antiviral therapy phase with a follow-up until
week 72, and the disease progression with a lifetime
perspective (see Fig. 1).
The second phase depends on the outcomes of the
first phase. The model is not limited to the immediate
treatment phase, but takes a lifetime perspective, be-
cause long-term complications associated with HCV are
very important for a chronic and severe disease like
HCV (Table 1). The transition probabilities of the eco-
nomic model are listed in Table 2. As no specific data for
the German context could be found, the model pri-
marily relies on a recent, systematic literature review
published as part of an English Health Technology Assess-
ment, which proved to be suitable for the purposes of our
model [21].
The model is run to simulate the treatment success of
the four therapeutic options for our efficiency frontier
analysis: PR, Boceprevir + PR, SOF/RBV, SOF/SMV.
The most important baseline characteristic of simu-
lated patients is the degree of fibrosis according to
the METAVIR scoring system. Each treatment is sim-
ulated for the duration as suggested by DGVS guide-
lines. After each treatment, patients can either have
undetectable HCV-RNA and achieve SVR or fail ther-
apy and be assigned to the relapser group. During
each treatment course, on-treatment adverse events
can appear. Furthermore, all-cause mortality was applied
to all possible health states according to German life tables
(not shown in Fig. 1 for simplicity). Detailed descrip-
tions of the model's mechanics have been published
elsewhere [19, 20].
In order to determine the influence of uncertainty
surrounding input parameters, we provide a multivariate
probabilistic sensitivity analysis. Parameter estimates were
varied within the uncertainty distributions that best reflect
Fig. 1 Model structure. The Markov model simulates both immediate treatment success and long-term disease progression. For simplicity, all-cause
mortality is not explicitly depicted
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the nature of each specific parameter. Uncertainty margins
are applied to each input parameter of interest based on
corresponding intervals provided in the literature (Table 2)
or based on assumptions if information is unavailable.
The standard error was assumed to vary 20 % around the
mean in case information on variance was not available
for a specific parameter (applied to German cost data in
Table 1).
We process 3000 simulations, which vary the parame-
ters by random draws from their assumed distributions
(as shown in Tables 1 and 2), to represent the uncer-
tainty of model results. We plot the 3000 simulations in
a scatterplot in Fig. 3 and compute the percentage of
simulations, in which SOF/SMV or SOF/RBV would be
above or on the efficiency frontier.
Results
As of August 2014, one week of SMV treatment costs €
3,829.91, while one week of SOF treatment costs € 4,714.69,
i.e. SOF/SMV combination therapy costs € 102,535.14 for
12 weeks, while SOF/RBV costs € 113,152.56 for 24 weeks
(DAA costs excluding RBV).
The main efficiency frontier for treatment-naive patients
as reported in Fig. 2 is defined by PR and Boceprevir triple
therapy. SVR was 46.62 % for treatment with PR for
treatment-naive patients. Boceprevir triple therapy im-
proved SVR rates to 58.58 %.
Boceprevir combination therapy increased costs from
€ 35,358.93 to € 52,679.70. The increase in total costs is
mainly due to € 23,606.10 in PI costs. Along with a
better SVR rate, long-term complications and the costs
Table 1 Costs of adverse events and long-term complications
On-treatment adverse events 2014 costs Source Probabilistic Sensitivity Analysis
Distribution Lower Upper
Anaemia 1,821.25 € [25] Gamma 1,457.00 € 2,185.50 €
Neutropenia 42.54 € expert opinion Gamma 34.03 € 51.05 €
Rash 26.85 € [25] Gamma 21.48 € 32.22 €
Pruritus 22.58 € [25] Gamma 18.06 € 27.10 €
Long-term complications
Decompensated cirrhosis 9,656.36 € [25] Gamma 7,725.09 € 11,587.63 €
Hepatocellular carcinoma 22,762.62 € [26] Gamma 18,210.10 € 27,315.14 €
First year after liver transplant 155,815.33 € [26] Gamma 124,652.26 € 186,978.40 €
Further years after liver transplant 22,534.99 € [26] Gamma 18,027.99 € 27,041.99 €
Table 2 Annual transition probabilities in the economic model
From To Mean SE Source Probabilistic Sensitivity Analysis
Distribution Lower Upper
F0-F2 F3 0.025 0.004 [21, 32] Beta 0.018 0.033
F3 F4 0.037 0.007 [21, 32] Beta 0.025 0.052
F4 DCC 0.039 0.010 [21, 33] Beta 0.022 0.061
HCC 0.014 0.010 [21, 33] Beta 0.002 0.039
SVR F4 DCC 0.000 0.000 expert opinion Beta 0.000 0.000
HCC 0.005 0.001 [34] Beta 0.004 0.007
DCC HCC 0.014 0.010 [21, 33] Beta 0.002 0.039
LT 0.020 0.003 [21, 35] Beta 0.015 0.026
LrD 0.130 0.010 [21, 33] Beta 0.111 0.150
HCC LT 0.020 0.003 [32, 35] Beta 0.015 0.026
LrD 0.430 0.030 [21, 33] Beta 0.372 0.489
LT LrD 0.150 0.023 [21, 36] Beta 0.109 0.197
pLT LrD 0.057 0.009 [21, 36] Beta 0.041 0.075
All-cause mortality Age/gender specific Life Tables, German
Federal Office of Statistics
DCC decompensated cirrhosis, HCC hepatocellular carcinoma, SVR sustained virologic response, LT liver transplant, LrD Liver related death, pLT post liver transplant,
fibrosis states F0-F4 according to METAVIR
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associated with them decreased. The introduction of
Boceprevir defined a required marginal efficiency of a
maximum of € 1,447.69 per additional SVR percentage
point gained. According to IQWIG’s efficiency frontier
concept, every new therapy for treating HCV can only cost
an additional € 1,447.69 for each additional SVR per-
centage point, which is gained by the new therapy beyond
the rate of 58.58 % which is achievable with Boceprevir
(Fig. 2).
In our modeling approach, IFN-free regimen SOF/RBV
achieves a rate of 47.37 %, which is below Boceprevir’s
SVR rate for treatment-naive patients. Therefore, the
required marginal efficiency of SOF/RBV cannot be
computed.
Our results show that the combination of SOF/SMV is
more effective and cheaper than SOF/RBV (Table 3).
SOF/SMV achieves a SVR rate of 93.31 %, i.e., adding
34.73 percentage points to the previously achievable
results with Boceprevir. Applying the efficiency frontier
cost per additional SVR percentage point, these SVR
rates result in maximum costs of € 102,963.08 for SOF/
SMV. In our model, SOF/SMV comes very close to this
threshold, even though no rebates have been negotiated
for SOF or SMV yet. Total costs are € 106,868.76
for SOF/SMV for 12 weeks, i.e., € 3,905.68 or 3.8 %
above the threshold defined with the efficiency frontier
approach.
Costs for IFN-free regimens are dominated by DAA
costs. For SOF/SMV, DAA costs are € 102,535.14. Along
with a much improved SVR rate, SOF/SMV saves €
5,152.67 in costs for long-term complications DCC,
HCC and LT.
The maximum cost defined by the efficiency frontier
can be met for SOF/SMV by negotiating a rebate of
6.9 % for SOF (lowering SOF’s 28-unit price from €
18,858.76 to € 17,556.86) or by negotiating a rebate of
8.5 % for SMV (lowering SMV’s 28-unit price from €
15,319.62 to € 14,017.72).
Our probabilistic sensitivity analysis shows that even
without any rebates, SOF/SMV meets the efficiency
frontier requirement in 10.0 % of the cases, while SOF/
RBV is never above or on the efficiency frontier at
current price levels (Fig. 3).
Discussion
The cost-effectiveness of HCV therapy has been sub-
ject to extensive research in Germany and served as a
proof of concept to establish the efficiency frontier
method [27, 28]. Since the introduction of DAAs, cost-
effectiveness analysis of drugs became more important
because antiviral treatment became a major cost compo-
nent in overall HCV treatment costs [29]. Other studies
used incremental life years or QALYs as a measure of
benefit for DAAs [20, 30, 31].
Fig. 2 Efficiency frontier. The efficiency frontier plots the required ratio of increases in sustained virologic response rates and costs, as defined by
comparators dual therapy (PR) and Boceprevir triple therapy
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For the first time in the history of the treatment of
chronic HCV, therapy regimens without the requirement
for IFN are available. Within few months, two different
regimens received conditional approval for the European
markets. SOF/RBV and SOF/SMV are the first oppor-
tunity for all-oral treatment without patients having to
face the side effects caused by IFN therapy. Both regi-
mens are more expensive than first generation DAAs
but save long-term costs for HCV complications.
As our application of the efficiency frontier shows, it is
a suitable method to plot both SVR rates and associated
long-term costs in one diagram. Due to the decisive
nature of SVR rates in the measurement of HCV therapy
success, no weighting algorithm is needed to aggregate
multiple parameters. Since the introduction of pricing
negotiations in 2011, no cost-effectiveness analysis has
been used yet to renegotiate an initial rebate agreement.
Our analysis shows that the efficiency frontier method is
suitable to serve such a purpose for DAAs in HCV
therapy.
Our model allows to report the immediate short-term
effectiveness of the available treatment regimens, while
calculating the impact of the treatment success on long-
term complications such as DCC, HCC and LT.
Application of the efficiency frontier approach shows
that SOF/SMV therapy almost meets the required thresh-
old, even though DAA prices have not been negotiated
yet. While our model incorporates long-term benefits in
terms of prevented long-term complications, it does not
incorporate the cost-savings associated with preventing
disease transmissions by untreated HCV patients.
Our study is limited by the lack of head-to-head
trials for direct comparison of SOF/SMV and SOF/
RBV treatment regimens. Our application of IQWIG’s
approach can be criticized for defining an efficiency
frontier with treatment regimens, which are not IFN-free
and lack a decisive benefit of SOF/RBV and SOF/SMV.
However, our results deliver data for the value of add-
itional SVR percentage points gained in the German SHI
system.
Table 3 Main modeling outcomes
Treatment naïves population
PR Boceprevir + PR SOF/RBV SOF/SMV
Clinical outcomes
SVR (24 weeks after tx) 46.62 % 58.58 % 47.37 % 93.31 %
Decompensated cirrhosis 11.88 % 10.07 % 10.64 % 1.73 %
Hepatocellular carcinoma 5.65 % 4.97 % 5.30 % 2.15 %
Liver Transplantation 1.42 % 1.22 % 1.27 % 0.26 %
Liver related death 13.52 % 11.71 % 12.22 % 3.22 %
Costs
Total Costs 35,358.93 € 52,679.70 € 127,891.69 € 106,868.76 €
Drug costs 21,842.68 € 41,842.96 € 117,578.96 € 103,641.74 €
Of which PI - € 23,606.10 € 113,152.56 € 102,535.14 €
Of which (P)R 21,842.68 € 18,236.86 € 4,426.40 € 1,106.60 €
Pre-treatment evaluation 170.99 € 85.00 € 85.00 € 85.00 €
Monitoring costs 1,287.97 € 1,207.16 € 1,084.00 € 878.97 €
Adverse event cost 450.07 € 923.49 € 7.00 € 162.53 €
SVR, F0-F2 50.75 € 66.06 € 46.86 € 94.11 €
SVR, F3 25.34 € 13.18 € 15.16 € 28.64 €
SVR, F4 63.40 € 27.77 € 31.94 € 60.34 €
F0-F2 703.42 € 491.51 € 778.50 € 72.15 €
F3 2,881.21 € 1,109.77 € 1,268.17 € 185.75 €
F4 1,258.16 € 1,082.28 € 1,105.84 € 187.26 €
DCC 2,963.85 € 2,595.90 € 2,614.33 € 450.92 €
HCC 1,459.78 € 1,307.52 € 1,348.52 € 588.77 €
LT 1,133.50 € 987.14 € 998.37 € 219.54 €
pLT 1,067.81 € 939.97 € 929.03 € 213.03 €
PR PegInterferon and Ribavirin, SOF Sofosbuvir, SMV Simeprevir, SVR sustained virologic response, PI protease inhibitor, fibrosis states F0-F4 according to METAVIR,
DCC decompensated cirrhosis, HCC hepatocellular carcinoma, LT, first year after liver transplant, pLT further years after liver transplant
Gissel et al. BMC Infectious Diseases  (2015) 15:297 Page 6 of 9
Our analysis confirms the findings of a recent study
conducted for the US context [31]. SOF/SMV is more
effective than SOF/RBV and saves costs both in Germany
and in the USA.
The new DAAs are more expensive but our modeling
approach shows that they prevent expensive long-term
complications more effectively than first generation
DAAs. While immediate drug costs are high, each case
of prevented LT equals savings of more than € 150,000
in the German SHI system.
Our analysis has shown that SOF/SMV is the most
cost-effective IFN-free therapy regimen at the moment.
Costs are lower for 12 weeks of SOF/SMV than for
24 weeks of SOF/RBV, both in terms of drug costs for
the antiviral therapy and in terms of prevented long-
term complications.
SOF/SMV requires therapy for only 12 weeks, which
could contribute to better patient compliance. The SVR
rate of more than 93 % is unprecedented for all-oral,
IFN-free HCV therapy and overall costs need to be low-
ered by less than 4 % to stay within the requirements of
the efficiency frontier.
Conclusions
The increase in clinical effectiveness by new DAA ap-
provals is unprecedented in HCV therapy. Contrary to
previous incremental improvements, recently approved
DAAs SOF and SMV represent a jump in clinical effect-
iveness. Health economic methods are required to put
the jumps in clinical effectiveness and the costs associ-
ated with the new therapies into perspective. Decision
makers in many jurisdictions need suitable tools for
cost-effectiveness analysis of the first IFN-free therapies
in order to make reimbursement decisions.
Our analysis has shown that IQWIG's efficiency frontier
approach is a suitable method to evaluate recent DAA
approvals SOF and SMV for IFN-free therapy. In addition
to higher sustained virologic response rates, the evaluated
therapies save long-term costs by preventing compli-
cations such as liver cirrhosis, hepatocellular carcinoma
and ultimately liver transplants, thereby offsetting part of
higher drug costs. IQWIG's efficiency frontier approach
can also be applied to further new approvals for the treat-
ment of HCV, which are expected in the near future.
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Fig. 3 Probabilistic sensitivity analysis. Probabilistic Sensitivity Analysis shows 3000 random draws for each of the four therapies. Out of the 3000
draws, SOF/SMV would be above or on the efficiency frontier in 10.0 % of the simulations, while SOF/RBV would never meet the requirement
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